- •Ospemifene is a novel selective estrogen receptor modulator for the treatment of vulvo-vaginal atrophy and dyspareunia.
- •This meta-analysis reviews all the published randomized controlled trials on the efficacy of ospemifene.
- •This drug seems to be an effective treatment for dyspareunia and vaginal dryness.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Ospemifene: first global approval.Drugs. 2013; 73: 605-612
- Vulvovaginal atrophy.Mayo Clin. Proc. 2010; 85: 87-94
- The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe.Maturitas. 2013; 75: 373-379
- Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women.Menopause. 2008; 15: 661-666https://doi.org/10.1097/gme.0b013e31815a5168
- The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.Sex. Med. 2014; 11: 487-497https://doi.org/10.1111/jsm.12377
- Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.Climateric. 2015; 19: 60-65https://doi.org/10.3109/13697137.2015.1113517
- Higgins J.P.T. Green S. Cochrane Handbook for Systematic Reviews of Interventions, v.5.1. Wiley-Blackwell, New Jersey2018 (updated March 2011. Cochrane Collaboration Web site. Available at:)
- Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.Menopause. 2003; 10: 433-439
- Ospemifene effectively treats vulvo- vaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.Menopause. 2010; 17: 480-486
- One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.Menopause. 2018; 20 (pp. 418/427)https://doi.org/10.1097/gme.0b013e31826d36ba
- Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.Climateric. 2014; 17: 173-182https://doi.org/10.3109/13697137.2013.834493
- Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.Menopause. 2018; 20 (pp. 623/630)https://doi.org/10.1097/gme.0b013e318279ba64
- Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment ovaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.Maturitas. 2014; 78: 91-98https://doi.org/10.1016/j.maturitas.2014.02.015
- In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer.J. Steroid Biochem. Mol. Biol. 2001; 77: 271-279
- Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.Climacteric. 2015; 18: 226-232
- A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses.PLoS One. 2013; 8